A randomized study of genetic education versus usual care in tumor profiling for advanced cancer in the ECOG-ACRIN Cancer Research Group (EAQ152).

"Conflict of Interest Disclosures Angela R. Bradbury reports research support and consulting fees from AstraZeneca and Merck. Angela M. DeMichele reports institutional research support from Pfizer, Genentech, Novartis, and Calithera. Kara N. Maxwell reports payment to her institution from the National Cancer Institute (K08CA215312). Keith T. Flaherty reports grants or contracts from Novartis and Sanofi; consulting fees from Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, Kinnate Pharmaceuticals, Scorpion Therapeutics, X4 Pharmaceuticals, PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Lilly, Novartis, Genentech, Bristol‐Myers Squibb, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre, and Debiopharm; participation on boards for X4 Pharmaceuticals, PIC Therapeutics, Sanofi, Amgen, Asana, Adaptimmune, Aeglea, Shattuck Labs, Tolero, Apricity, Oncoceutics, Fog Pharma, Neon, Tvardi, xCures, Monopteros, Vibliome, ALX Oncology, Lilly, Novartis, Genentech, Bristol‐Myers Squibb, Merck, Takeda, Verastem, Boston Biomedical, Pierre Fabre, and Debiopharm; leadership or fiduciary roles with Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, Kinnate Pharmaceuticals, and Scorpion Therapeutics; and stock or stock options in Loxo Oncology, Clovis Oncology, Strata Oncology, Vivid Biosciences, Checkmate Pharmaceuticals, Kinnate Pharmaceuticals, Scorpion Therapeutics, X4 Pharmaceuticals, PIC Therapeutics, Apricity, Oncoceutics, Fog Pharma, Tvardi, xCures, Monopteros, Vibliome, and ALX Oncology. Stefan C. Grant reports funding support from Guardant Health and a stipend for serving as vicechair of a steering committee for the Precision Medicine Exchange Consortium. Ruth C. Carlos reports travel reimbursement from ECOG‐ACRIN, RSNA, ARRS, and ARBIR; participation on a data safety monitoring board for ECOG‐ACRIN; stock or stock options in ARBIR; and salary support from JACR. Lynne I. Wagner reports consulting fees from Celgene (Bristol‐Myers Squibb) and Athenex. The other authors made no disclosures."

"National Institutes of Health 10.13039/100000002"

"This trial has been registered at ClinicalTrials.gov (NCT02823652)."